OBJECTIVE
To study oncological outcomes after radical cystectomy (RC) for bladder cancer (BC) in women
MATERIAL AND METHODS
A total of 120 RCs were performed in women with BC in 2003 to 2018. Their mean age was 63.5±1.0 (29-84) years. Eighty-nine (74.2%) patients had muscle-invasive BC; 31 (25.8%) had non-muscle-invasive BC. There was locally advanced BC in 40% of patients and lymph node metastases in 21 (17.5%). Urothelial carcinoma was present in 112 (93.3%) patients. An orthotopic reservoir was formed in 71 (59.2%) patients. The Kaplan-Meier method was used to estimate survival eares. Calculations were performed using the SPSS Statistics 16 computer program for statistical data processing.
RESULTS
The long-term results were studied within 37.5 months after surgery (95% CI, 29.0-48.0). During this period, there were 57 deaths: from BC progression in32 cases (a local recurrence was only in 3 (2.5%) cases), from the causes associated with surgical peculiarities in 2, and from other causes in 23. The 5-year overall survival rate was 55.4% (median, 83 months). The 5-year overall survival rates were 87.9%, 67.9%, 67.9%, and 5% in patients with pT1, pT2, pT3, and pT4a, respectively (p<0.001); 64.7% in patients with pN0 (median, 108 months) and 9.5% in those with pN1 (median, 13 months) (p<0.001). The 5-year cancer-specific survival rate was 68.8%; the median was not reached. The 5-year cancer-specific survival rate was 91.1%, 83.9%, 59.7%, and 6.6% in patients with pT1, pT2, pT3, and pT4, respectively (p<0.001); 79.1% in patients with pN0 and 12.7% in those with pN1 (p<0.001).
CONCLUSION
There are high long-term survival rates after RC performed in women with early-stage BC. The survival rates are extremely low in patients with locally advanced BC or metastases. To improve the results of RC in this category of patients, it is necessary to use current systemic therapy regimens.